For decades, cosmetics were the least-regulated category the FDA touched. A skincare founder could formulate, fill, and sell with remarkably little federal oversight. That era is over. The Modernization of Cosmetics Regulation Act (MoCRA) is the biggest change to U.S. cosmetics law in generations, and if you're building a skincare brand, it quietly rewrote your to-do list. Here's what it is and what you need to build around.

What MoCRA is

MoCRA gave the FDA meaningful authority over cosmetics for the first time in a serious way. Where the old regime largely relied on companies to police themselves, MoCRA adds real obligations: registering your facility, listing your products, keeping safety records, reporting when something goes wrong, and getting your labels right, all backed by the FDA's new power to order a recall.

None of this should scare a serious founder. It's structure, and structure is something you can plan for. The founders who struggle are the ones who discover these requirements after they've committed to a formula and a manufacturer. The ones who thrive build the requirements into the product from day one.

The core obligations skincare founders must build around

Facility registration

Facilities that manufacture or process cosmetics for the U.S. market are expected to register with the FDA and renew that registration periodically. If you're using a contract manufacturer, this is one of the first questions to ask them. A quality-focused, FDA-registered facility should already have this handled, but it's on you to confirm.

Product listing

Each cosmetic product is expected to be listed with the FDA, including its ingredients. This isn't approval (listing is not the FDA blessing your product), but it does mean your formula and ingredient disclosure need to be accurate and ready before you go to market.

Safety substantiation

This is the heart of MoCRA. You're expected to maintain records demonstrating that your product is safe under labeled or customary conditions of use. “We think it's fine” is not substantiation. Documented reasoning, appropriate testing, and ingredient-level rationale are. For a founder, this is the single most important habit to establish early, because you cannot retroactively manufacture a paper trail you never created.

Adverse-event reporting

You're expected to have a way to receive and track adverse-event reports tied to your products, and to report serious ones to the FDA. Practically, that means a real intake process (a monitored contact channel, records, and a plan), not a form no one checks.

Labeling updates

MoCRA tightened labeling expectations, including a compliant contact for adverse-event reporting and, over time, fragrance-allergen disclosure. Your label is a regulatory document, not just a design surface, and it needs the same discipline as your formula.

FDA recall authority

For the first time, the FDA can order a mandatory recall of a cosmetic it deems unsafe. Previously recalls were voluntary. This raises the stakes on everything above: safety substantiation and clean records are now what protect you if a product is ever questioned.

MoCRA didn't just add paperwork. It moved skincare from “prove it if we ask” to “have it ready before you sell.” The brands built for that shift are the ones with documentation, not just a nice bottle.

The founder's shortcut: treat safety substantiation and labeling as part of the product itself, formulated alongside the cream, not as compliance chores bolted on before launch. Documentation you build during development is an asset; documentation you scramble for at launch is a liability.

What this means for how you develop a product

MoCRA rewards founders who bring science and documentation to the front of the process. That's a mindset shift from the old skincare playbook of “pick a stock formula, slap on a label, sell.” A MoCRA-aware approach looks like this:

  • Formulate with substantiation in mind: choose ingredients and concentrations you can defend, and keep the rationale.
  • Plan cosmetic claims carefully. “Supports the appearance of” is a cosmetic claim; “heals” or “treats” a skin condition edges toward a drug claim and a very different regulatory pathway. Claims guardrails belong in the plan, not the afterthought.
  • Confirm your manufacturer's status: registration, cGMP practices, and their ability to support your record-keeping.
  • Build the label as a compliance artifact, with the required contact, disclosures, and honest language.

This is precisely the way we approach skincare product development: MoCRA-aware from the first formulation decision, with the safety documentation and claims strategy built alongside the product you own. For providers extending their practice into retail, the same discipline underpins med spa product line development, where a defensible, well-documented product is what lets you sell with confidence.

The bottom line

MoCRA didn't make skincare harder to launch. It made it harder to launch carelessly. Facility registration, product listing, safety substantiation, adverse-event reporting, tighter labeling, and recall authority all point the same direction: the brands that win are the ones designed around documentation and safety from the start. If you're building something you intend to own and scale, that discipline isn't a burden. It's your moat. And if you're weighing a proprietary product against an off-the-shelf one, it's worth reading Private Label vs. Custom Formulation with MoCRA in mind.

This article is educational and is not legal or regulatory advice. Product claims, labels, and category decisions should be reviewed by qualified regulatory and legal professionals before launch.